Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma

He,Jiliang; Zhang,Peng; Li,Qinghu; Zhou,Dongsheng; Liu,Ping

doi:10.3892/ol.2015.3907

Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma

Authors:
- Jiliang He
- Peng Zhang
- Qinghu Li
- Dongsheng Zhou
- Ping Liu
View Affiliations

Affiliations: Department of Orthopaedics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: November 10, 2015 https://doi.org/10.3892/ol.2015.3907
Pages: 293-298

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The high mobility group box 1 (HMGB1) protein functions as an extracellular signaling molecule that is critical in inflammation and carcinogenesis. The HMGB1 protein is actively secreted by natural killer cells, monocytes and macrophages, and acts as an inflammatory cytokine. The present study enrolled 174 patients that underwent a tumorectomy between 2006 and 2013 in Shandong Provincial Hospital. The age of the patients ranged between 13 and 74 years, with a median age of 27 years. The tumors of the patients were staged according to the Union for International Cancer Control 2009 tumor‑node‑metastasis tumor staging system. Nuclear grading was based on the Fuhrman grading system. In the osteosarcoma tissue samples, HMGB1 expression was detected in 84 samples (48.3%) with a low immunoreactivity and in 90 samples (51.7%) with a high immunoreactivity. The association between clinicopathological characteristics and tumor cell HMGB1 expression (low vs. high) was summarized. The association between HMGB1 expression and tumor size, tumor stage and nuclear grade was statistically significant (P=0.034, 0.008 and 0.019, respectively). There was no significant association between HMGB1 expression and the age of the patients (P=0.335; Table I). The current study demonstrated that patients with a high HMGB1 expression (>50% cells expressing HMGB1) had poorer survival rates, and therefore a poorer prognosis, compared with patients with low HMGB1 immunostaining (10‑50% cells expressing HMGB1). The results of the present study suggest that higher expression levels of HMGB1 are significantly associated with a poorer prognosis and may act as a marker for prognosis in osteosarcoma, particularly osteosarcoma recurrence. Additional studies investigating the biological features of HMGB1 may confirm the potential role of HMGB1 as a novel target for anticancer therapy in osteosarcoma.

View Figures

View References

1	Broadhead ML, Dass CR and Choong PF: Systemically administered PEDF against primary and secondary tumours in a clinically relevant osteosarcoma model. Br J Cancer. 105:1503–1511. 2011. View Article : Google Scholar : PubMed/NCBI
2	Mirabello L, Troisi RJ and Savage SA: International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 125:229–234. 2009. View Article : Google Scholar : PubMed/NCBI
3	Cong Y, Li CJ, Zhao JN, Liu XZ and Shi X: Associations of polymorphisms in the bone morphogenetic protein-2 gene with risk and prognosis of osteosarcoma in a Chinese population. Tumour Biol. 36:2059–2064. 2015. View Article : Google Scholar : PubMed/NCBI
4	Zhang F, Huang W, Sheng M and Liu T: MiR-451 inhibits cell growth and invasion by targeting CXCL16 and is associated with prognosis of osteosarcoma patients. Tumour Biol. 36:2041–2048. 2015. View Article : Google Scholar : PubMed/NCBI
5	Briccoli A, Rocca M, Salone M, Guzzardella GA, Balladelli A and Bacci G: High grade osteosarcoma of the extremities metastatic to the lung: Long-term results in 323 patients treated combining surgery and chemotherapy, 1985–2005. Surg Oncol. 19:193–199. 2010. View Article : Google Scholar : PubMed/NCBI
6	Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
7	Ren K, Yao N, Wang G, Tian L, Ma J, Shi X, Zhang L, Zhang J, Zhou X, Zhou G, et al: Vasculogenic mimicry: A new prognostic sign of human osteosarcoma. Hum Pathol. 45:2120–2129. 2014. View Article : Google Scholar : PubMed/NCBI
8	Seftor RE, Hess AR, Seftor EA, Kirschmann DA, Hardy KM, Margaryan NV and Hendrix MJ: Tumor cell vasculogenic mimicry: From controversy to therapeutic promise. Am J Pathol. 181:1115–1125. 2012. View Article : Google Scholar : PubMed/NCBI
9	Schmidt T and Carmeliet P: Angiogenesis: A target in solid tumors, also in leukemia? Hematology Am Soc Hematol Educ Program. 2011:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
10	Fukumura D, Duda DG, Munn LL and Jain RK: Tumor microvasculature and microenvironment: Novel insights through intravital imaging in pre-clinical models. Microcirculation. 17:206–225. 2010. View Article : Google Scholar : PubMed/NCBI
11	Cao Z, Bao M, Miele L, Sarkar FH, Wang Z and Zhou Q: Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: A systemic review and meta-analysis. Eur J Cancer. 49:3914–3923. 2013. View Article : Google Scholar : PubMed/NCBI
12	Cao Z, Shang B, Zhang G, Miele L, Sarkar FH, Wang Z and Zhou Q: Tumor cell-mediated neovascularization and lymphangiogenesis contrive tumor progression and cancer metastasis. Biochim Biophys Acta. 1836:273–286. 2013.PubMed/NCBI
13	Liu YR, Sun B, Zhao XL, Gu Q, Liu ZY, Dong XY, Che N and Mo J: Basal caspase-3 activity promotes migration, invasion, and vasculogenic mimicry formation of melanoma cells. Melanoma Res. 23:243–253. 2013.PubMed/NCBI
14	Alexandrova EA and Beltchev BG: Acetylated HMG1 protein interacts specifically with homologous DNA polymerase alpha in vitro. Biochem Biophys Res Commun. 154:918–927. 1988. View Article : Google Scholar : PubMed/NCBI
15	Bonaldi T, Längst G, Strohner R, Becker PB and Bianchi ME: The DNA chaperone HMGB1 facilitates ACF/CHRAC-dependent nucleosome sliding. EMBO J. 21:6865–6873. 2002. View Article : Google Scholar : PubMed/NCBI
16	Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191–195. 2002. View Article : Google Scholar : PubMed/NCBI
17	Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A and Lotze MT: Masquerader: High mobility group box-1 and cancer. Clin Cancer Res. 13:2836–2848. 2007. View Article : Google Scholar : PubMed/NCBI
18	Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A and Tracey KJ: Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery. 126:389–392. 1999. View Article : Google Scholar : PubMed/NCBI
19	Tang D, Kang R, Van Houten B, Zeh HJ, Billiar TR and Lotze MT: High mobility group box 1 (HMGB1) phenotypic role revealed with stress. Mol Med. 20:359–362. 2014. View Article : Google Scholar : PubMed/NCBI
20	Luo Y, Chihara Y, Fujimoto K, Sasahira T, Kuwada M, Fujiwara R, Fujii K, Ohmori H and Kuniyasu H: High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. Eur J Cancer. 49:741–751. 2013. View Article : Google Scholar : PubMed/NCBI
21	Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, et al: Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 8:487–496. 2007. View Article : Google Scholar : PubMed/NCBI
22	Lin T, Sammy F, Yang H, Thundivalappil S, Hellman J, Tracey KJ and Warren HS: Identification of hemopexin as an anti-inflammatory factor that inhibits synergy of hemoglobin with HMGB1 in sterile and infectious inflammation. J Immunol. 189:2017–2022. 2012. View Article : Google Scholar : PubMed/NCBI
23	Zhang G, Chen F, Cao Y, Amos JV, Shah G and See WA: HMGB1 release by urothelial carcinoma cells in response to Bacillus Calmette-Guérin functions as a paracrine factor to potentiate the direct cellular effects of Bacillus Calmette-Guérin. J Urol. 190:1076–1082. 2013. View Article : Google Scholar : PubMed/NCBI
24	Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 27:61992009. View Article : Google Scholar : PubMed/NCBI
25	Fuhrman SA, Lasky LC and Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
26	Broadhead ML, Clark JC, Myers DE, Dass CR and Choong PF: The molecular pathogenesis of osteosarcoma: A review. Sarcoma. 2011:9592482011. View Article : Google Scholar : PubMed/NCBI
27	Aragon-Ching JB and Maki RG: Treatment of adult soft tissue sarcoma: Old concepts, new insights, and potential for drug discovery. Cancer Invest. 30:300–308. 2012. View Article : Google Scholar : PubMed/NCBI
28	Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program. Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
29	Kong C and Hansen MF: Biomarkers in osteosarcoma. Expert Opin Med Diagn. 3:13–23. 2009. View Article : Google Scholar : PubMed/NCBI
30	Laverdiere C, Hoang BH, Yang R, Sowers R, Qin J, Meyers PA, Huvos AG, Healey JH and Gorlick R: Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res. 11:2561–2567. 2005. View Article : Google Scholar : PubMed/NCBI
31	Somers GR, Ho M, Zielenska M, Squire JA and Thorner PS: HER2 amplification and overexpression is not present in pediatric osteosarcoma: A tissue microarray study. Pediatr Dev Pathol. 8:525–532. 2005. View Article : Google Scholar : PubMed/NCBI
32	Osaka E, Suzuki T, Osaka S, Yoshida Y, Sugita H, Asami S, Tabata K, Hemmi A, Sugitani M, Nemoto N and Ryu J: Survivin as a prognostic factor for osteosarcoma patients. Acta Histochem Cytochem. 39:95–100. 2006. View Article : Google Scholar : PubMed/NCBI
33	Shen X, Hong L, Sun H, Shi M and Song Y: The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer. Oncol Rep. 22:535–539. 2009.PubMed/NCBI
34	Liu F, Zhang Y, Peng Z, Gao H, Xu L and Chen M: High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. J Transl Med. 10:1352012. View Article : Google Scholar : PubMed/NCBI
35	Chuangui C, Peng T and Zhentao Y: The expression of high mobility group box 1 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. Pathol Oncol Res. 18:1021–1027. 2012. View Article : Google Scholar : PubMed/NCBI
36	Chen J, Xi B, Zhao Y, Yu Y, Zhang J and Wang C: High-mobility group protein B1 (HMGB1) is a novel biomarker for human ovarian cancer. Gynecol Oncol. 126:109–117. 2012. View Article : Google Scholar : PubMed/NCBI
37	Liu Y, Xie C, Zhang X, Huang D, Zhou X, Tan P, Qi L, Hu G, Tian Y and Qiu Y: Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer. 46:3007–3015. 2010. View Article : Google Scholar : PubMed/NCBI
38	Hao Q, Du XQ, Fu X and Tian J: Expression and clinical significance of HMGB1 and RAGE in cervical squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi. 30:292–295. 2008.(In Chinese). PubMed/NCBI
39	Kang HJ, Lee H, Choi HJ, Youn JH, Shin JS, Ahn YH, Yoo JS, Paik YK and Kim H: Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers. Lab Invest. 89:948–959. 2009. View Article : Google Scholar : PubMed/NCBI
40	Topalova D, Ugrinova I, Pashev IG and Pasheva EA: HMGB1 protein inhibits DNA replication in vitro: A role of the acetylation and the acidic tail. Int J Biochem Cell Biol. 40:1536–1542. 2008. View Article : Google Scholar : PubMed/NCBI
41	Schlueter C, Weber H, Meyer B, Rogalla P, Röser K, Hauke S and Bullerdiek J: Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol. 166:1259–1263. 2005. View Article : Google Scholar : PubMed/NCBI
42	Sitohy B, Nagy JA and Dvorak HF: Anti-VEGF/VEGFR therapy for cancer: Reassessing the target. Cancer Res. 72:1909–1914. 2012. View Article : Google Scholar : PubMed/NCBI
43	Wang W, Jiang H, Zhu H, Zhang H, Gong J, Zhang L and Ding Q: Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma. Oncol Lett. 5:884–888. 2013.PubMed/NCBI
44	Tang D, Kang R, Zeh HJ III and Lotze MT: High-mobility group box 1 and cancer. Biochim Biophys Acta. 1799:131–140. 2010. View Article : Google Scholar : PubMed/NCBI
45	Xiao J, Ding Y, Huang J, Li Q, Liu Y, Ni W, Zhang Y, Zhu Y, Chen L and Chen B: The association of HMGB1 gene with the prognosis of HCC. PLoS One. 9:e890972014. View Article : Google Scholar : PubMed/NCBI
46	Yonemoto T, Tatezaki S, Ishii T, Satoh T, Kimura H and Iwai N: Prognosis of osteosarcoma with pulmonary metastases at initial presentation is not dismal. Clin Orthop Relat Res. 349:194–199. 1998. View Article : Google Scholar : PubMed/NCBI
47	Daw NC, Billups CA, Rodriguez-Galindo C, McCarville MB, Rao BN, Cain AM, Jenkins JJ, Neel MD and Meyer WH: Metastatic osteosarcoma. Cancer. 106:403–412. 2006. View Article : Google Scholar : PubMed/NCBI